P/E ratio for Bio-Rad Laboratories (BIO)
P/E ratio as of January 2023 (TTM): -2.37
According to Bio-Rad Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.37344. At the end of 2021 the company had a P/E ratio of 5.30.
P/E ratio history for Bio-Rad Laboratories from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 5.30 | 16.25% |
| 2020 | 4.56 | -27.43% |
| 2019 | 6.28 | -67.07% |
| 2018 | 19.1 | -69.17% |
| 2017 | 61.8 | -67.44% |
| 2016 | 190 | 429.94% |
| 2015 | 35.8 | -8.46% |
| 2014 | 39.1 | -14.5% |
| 2013 | 45.8 | 160.61% |
| 2012 | 17.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 23.1 | -1,073.35% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | 32.0 | -1,447.95% | 🇺🇸 USA |
 Agilent Technologies A | 37.1 | -1,661.83% | 🇺🇸 USA |
 Becton Dickinson BDX | 42.5 | -1,892.22% | 🇺🇸 USA |
 General Electric GE | -15.1 | 534.13% | 🇺🇸 USA |
 Danaher DHR | 28.9 | -1,318.10% | 🇺🇸 USA |
 PerkinElmer
PKI | 28.2 | -1,286.73% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.